Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Kimberly G Brodovicz"'
Autor:
Soulmaz Fazeli Farsani, Atsushi Taniguchi, Rie Ikeda, Kimberly G Brodovicz, Dorothee B Bartels
Publikováno v:
Journal of Diabetes Investigation, Vol 10, Iss 5, Pp 1246-1253 (2019)
Abstract Aims/Introduction To evaluate linagliptin prescribing in type 2 diabetes mellitus patients with different comorbidities, an expanded Japanese post‐marketing surveillance also collected baseline data for patients initiating other glucose‐
Externí odkaz:
https://doaj.org/article/999ebdc7248d4215b0f3a08279cd1992
Autor:
Gregory A. Nichols, Anouk Derúaz-Luyet, Kimberly G. Brodovicz, Teresa M. Kimes, A. Gabriela Rosales, Sibylle J. Hauske
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Studies of progression of kidney dysfunction typically focus on renal replacement therapy or percentage decline in estimated glomerular filtration rate (eGFR) as outcomes. Our aim was to compare real-world patients with and withou
Externí odkaz:
https://doaj.org/article/66c7c64e37904a3a9743fe0e13d010c1
Autor:
Yanni Fan, Ling Zhang, Monik C Jiménez, Rhonda L Bohn, Jennifer S Thompson, Kimberly G Brodovicz, Stephani Gray, Gil Y Melmed
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:400-408
Autor:
Mark G. Lebwohl, Rose Anne Medeiros, Rachel H. Mackey, Wendell C. Valdecantos, Kimberly G. Brodovicz, Apinya Lertratanakul, Bruce Strober
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 8:56-65
Background Palmoplantar pustulosis (PPP) is a rare skin disease characterized by episodes of neutrophilic pustules on the palms of the hands and soles of the feet. Current treatments for PPP have limited efficacy, and there is little real-world evide
Autor:
Elisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, Jessica M. Franklin, Anouk Déruaz‐Luyet, Kimberly G. Brodovicz, Adrian J. Santiago Ortiz, Lily G. Bessette, Martin Kulldorff, Sebastian Schneeweiss
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 1, Pp n/a-n/a (2020)
Abstract Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effe
Externí odkaz:
https://doaj.org/article/3b1d4ccae1a34e5da8d6f66e7b2e3401
Autor:
Yanni Fan, Ling Zhang, Negar Omidakhsh, Rhonda L Bohn, Jennifer S Thompson, Kimberly G Brodovicz, Parakkal Deepak
Publikováno v:
Inflammatory Bowel Diseases. 29:914-922
Background Crohn’s disease (CD) is a chronic autoimmune disease in which inflammation can progress to complications of stricturing and/or penetrating disease. Real-world data on burden of complicated CD phenotypes are limited. Methods We analyzed c
Autor:
Gregory A. Nichols, Anouk Déruaz-Luyet, Kimberly G. Brodovicz, Teresa M. Kimes, A. Gabriela Rosales, Sibylle J. Hauske
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/f5b7eeffd4ef433b883725981725a1ef
Autor:
Anouk Deruaz-Luyet, Anastasia Ustyugova, Kimberly G. Brodovicz, Gregory A. Nichols, Maureen O’Keeffe-Rosetti
Publikováno v:
J Am Soc Nephrol
Background CKD is associated with higher health care costs that increase with disease progression. However, research is lacking on the type of health care costs associated with CKD across all stages in a general population with a substantial comorbid
Autor:
Elizabeth M. Garry, Christina Raabe, Anouk Deruaz-Luyet, Lawrence A. Lavery, Kimberly G. Brodovicz
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the incidence of lower extremity amputation (LEA) among patients with type 1 diabetes (T1D) and patients with type 2 diabetes (T2D) with those without diabetes using US commercial claims and to assess the presence of key co‐morbiditi
Autor:
Deborah J. Wexler, Mehdi Najafzadeh, Ajinkya Pawar, Lily G. Bessette, Anouk Deruaz-Luyet, Patorno E Elisabetta, Sebastian Schneeweiss, Julie M. Paik, Robert J. Glynn, Kimberly G. Brodovicz
Publikováno v:
Diabetes Obes Metab
Objective Over 99% of the EMPA-REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin vs dipeptidyl pep